Hepatitis/MASH

Antiretroviral drug interactions now included due to high prevalence of HIV coinfection among patients with hepatitis C virus.

How treatment with Harvoni changed the life of a patient infected with HCV.

Patients simultaneously registering at multiple centers had higher transplant rates, lower death rates waiting for a transplant, and greater income.

Side effects, familial support and liver condition among factors that influence hepatitis C treatment decisions.

HCV drug combination may cut treatment time by 75%.

Direct-acting antivirals may help eradicate hepatitis C virus in patients who recently had a liver transplant, reducing the need for further transplants.

Combination of sofosbuvir and simeprevir may have an unexpected side effect in HCV therapy.

Lawsuits challenge access denials to curative hepatitis C drugs among incarcerated individuals infected with the disease.

Liver disease experts suggest how to prioritize the treatment of different HCV patient groups.

Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.

The once daily oral medication is for use with Sovaldi with or without ribavirin or in combination with peginterferon alfa and ribavirin.

Once-daily combination would be the first all-oral, pan-genotypic single tablet for treatment of HCV.

The FDA is reviewing Gilead Sciences' new drug application (NDA) for a fixed dose combination of sofosbuvir (Solvadi) and velpatasvir to treat genotype 1-6 hepatitis C virus infection.

Hepatic decompensation and liver failure in patients with underlying liver cirrhosis more common with drug regimen.

Many RA treatments suppress the immune system, leaving patients at risk for contracting a potentially fatal infection.

Panel discusses treatment barriers during annual NASP conference.

Immune mechanisms found to have significant impact on overcoming HCV.

Pan-virals show potential to work across all HCV genotypes.

Injection drug use most frequently linked to a positive hepatitis C screening.

Chronic hepatitis C infection linked to the prevalence of plaque and noncalcified plaque in the arteries.

Targeted drug delivery focuses on diseased cells to minimize side effects on normal cells.

Expansion addresses patients co-infected with HIV, patients with advanced cirrhosis, and patients with post-liver transplant HCV recurrence.